Table 2 Clinical trials of ICIs combination approaches in cervical cancers and sintilimab-based regimens in different tumor types
Drugs | Identifier | Phase | Intervention model | Simple size | Stage | Pathology | ORRa(%)(95CI) | mOS(months)(95CI) |
|---|---|---|---|---|---|---|---|---|
ICIs combined with NACT | ||||||||
 Pem 200 mg + Platinum + PTX 175 mg/m2 | NCT03635567 | III | double-blind | 308 | M/R/P | SCC/ACC/ASC | 65.9 | 10.4 |
 BEV 15 mg/kg + Platinum + Taxanes | NCT00803062 | III | Single-arm | 227 | M/R/P | SCC/ACC/ASC | 49.3 | 16.8 |
 BEV 15 mg/kg + Platinum + PTX 175 mg/m2 | NCT03556839 | III | Single-arm | 202 | M/R/P | SCC/ACC/ASC | NA | NA |
 Ate 1200 mg + BEV 15 mg/kg + Platinum + PTX 175 mg/m2 | NCT03556839 | III | Single-arm | 202 | M/R/P | SCC/ACC/ASC | NA | NA |
 BCD-100 3 mg/kg + Platinum + PTX 175 mg/m2 | NCT03912415 | III | double-blind | 158 | M/R/P | SCC/ACC/ASC | NA | NA |
 Tis 200 mg + Platinum + Taxanes | NCT05013268 | I | Single-arm | 15 | LACC | SCC | NA | NA |
 Sin 200 mg + PTX 150 mg/m2 + Cis 70 mg/m2 | NCT04799639 | II | Single-arm | 47 | LACC | SCC/ACC/ASC | NA | NA |
Sintilimab-based regimensb | ||||||||
 Sin 200 mg + CBP AUC5 + GEM 1000 mg/m2 | ChiCTR1900023758 | II | Single-arm | 50 | IIIA | NSCLC | 46 | 85.3(NA) |
 Sin 200 mg + CBP AUC5 + PTX 135 mg/m2 | ChiCTR1900026593 | II | Single-arm | 47 | II-IVA | ESCC | 25.5 | 14.6(11.3–24.0) |
 Sin 2 mg/kg + OXA 130 mg/m2 + CAP 1000 mg/m2 | ChiCTR2000030414 | II | Single-arm | 30 | cT3/4aN + M0 | GAC | 70 | 13(3.5–19.3) |
 Sin 200 mg + Platinum + Taxanes | NCC2017A24 | II | Single-arm | 96 | II–IVA | ESCC | 62.5 | 8.9(6.2–14.3) |
 Sin 200 mg + DTX 75 mg/m2 | ChiCTR2000030414 | II | Single-arm | 30 | III-IV | NSCLC | 36.7 | 13.4(6.37–20.43) |